Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell(Yale University), John R. Mackey(University of Alberta)
Cited by 448
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
|Journal of Clinical Oncology|2009|850
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
|British Journal of Cancer|2008|651
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
|JNCI Journal of the National Cancer Institute|2013|333